15 Mar 2017

London, 15 March 2017- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceu!cal company focused on rare and specialty diseases, confirms that the Annual Report and Accounts for the year ended 31 December 2016, the Notice of the Annual General Meeting and a Form of Proxy were posted to shareholders on 14 March 2017.

The Annual General Meeting is to be held on Tuesday 27 June 2017 at 10.00am BST at the offices of Proskauer Rose (UK) LLP, 110 Bishopsgate, London EC2N 4AY.

A copy of the Annual Report & Accounts and Notice of Annual General Meeting is available on the Company's website: www.mereobiopharma.com.

For further enquiries:

Mereo BioPharma Group plc
+44 (0)333 023 7319
Denise Scots-Knight, ChiefExecutive Officer
Richard Jones, Chief Financial Officer

Nominated Adviser and Joint Broker
CantorFitzgerald Europe
+44 (0)20 7894 7000
Phil Davies
Will Goode

Joint Broker
RBC Capital Markets
+44 (0)20 7653 4000
Rupert Walford
Laura White

Public Relations Adviser to Mereo Biopharma
FTI Consulting
+44 (0)20 3727 1000
Ben Atwell
Simon Conway
Brett Pollard

About Mereo

Mereo is a UK-based biopharmaceutical company focused on the development of innovative medicines that aim to address unmet medical needs in rare and specialty disease areas and improve patient quality of life.The Company seeks to selectively acquire development-stage product candidates with demonstrated clinically meaningful data from large pharmaceutical companies and to rapidly progress these product candidates to subsequent value inflection points.

Mereo combines the operational discipline and efficiency of a small company with the financial resources to conduct comprehensive clinical studies.The Company has the option to directly commercialise products, for example in orphan diseases, in addition to partnering or divesting its products.

Mereo's initial portfolio consists of three mid-late stage clinical assets that were acquired from Novartis in July 2015. BPS- 804 is being developed for the prevention of fractures resulting from osteogenesis imperfecta(brittle bone disease); acumapimod (BCT-197), is being developed to treat inflammation in patients with an AECOPD; and BGS-649 isa once-weekly pill to restore normal testosterone levels in men with hypogonadotropic hypogonadism.

In H1 2016 the Company initiated a Phase 2 study with acumapimod and a Phase 2b study with BGS-649. Mereo expects to commence the first pivotal trial for BPS-804 during H1 2017. Additional product opportunities, from a range of large pharmaceutical and biotechnology companies, are underactive evaluation.